Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Can we get some (all) folks voting for #1 or #2, please?
𝘊𝘢𝘳𝘥𝘪𝘰𝘭𝘰𝘨𝘪𝘴𝘵𝘴 𝘖𝘯𝘭𝘺!
— Angry Cardiologist (@AngryCardio) February 5, 2023
How often do you prescribe Vascepa (icosapent ethyl) for the labeled indication: adjunct to statins, TG ≥ 150 mg/dL & h/o CAD or DM?
I find it funny and very satisfying that we went from Amarin tweeting #TeamAmain (Amain)
(original tweet deleting) to Denner creating FreeAmarin.com websiteWtf is wrong with the people who prepare their idiotic tweets?
— Val (@Valmcd10) April 22, 2022
What's happening in the sky?!
#FreeAmarin @Amarincorp #VoteBlue #Vascepa #Balloonhttps://t.co/95VrJ7oNiM pic.twitter.com/OJ7Dk7BYYE
— Raf 🍊 (@ra_fun) February 4, 2023
Take a look at 1 year ago, the scripts were struggling. Today, the scripts are 23.5% lower than that (y/y). The glass is empty.
Scripts for week ending January 27, 2023
Drug Industry TRx: -0.5% w/w; +7.1% y/y
Vascepa
TRx 57,799; -0.8% (-465) w/w; -23.5% y/y
NRx 27,009; -1.1% (-293) w/w; -25.5% y/y
Ref 30,789; -0.6% (-172) w/w; -21.7% y/y
Fake Vascepa
TRx 44,735; -6.0% (-2,852) w/w; As % of total V: 43.6%
NRx 22,311; -6.0% (-1,419) w/w; As % of total V: 45.2%
Ref 22,424; -6.0% (-1,433) w/w; As % of total V: 42.1%
Fake Vascepa by Manufacturer
Hikma - TRx 16,958; -24 w/w; Generic share 37.9%; Total V share 16.5%
Reddy - TRx 19,024; -2,680 w/w; Generic share 42.5%; Total V share 18.6%
Apotex - TRx 8,347; -143 w/w; Generic share 18.7%; Total V share 8.1%
Teva - TRx 407; -4 w/w; Generic share 0.9%; Total V share 0.4%
Vascepa + Fake Vascepa
TRx 102,534; -3.1% (-3,316) w/w; +0.6% y/y
NRx 49,321; -3.4% (-1,711) w/w; -5.3% y/y
Ref 53,213; -2.9% (-1,605) w/w; +6.6% y/y
Lovaza (Fake & Brand)
TRx 63,476; -2.2% (-1,429) w/w; +1.2% y/y
NRx 32,164; -0.8% (-268) w/w; -3.7% y/y
Ref 31,312; -3.6% (-1,161) w/w; +6.8% y/y
Psychological breakdown of NS (not an insult):
Loyal, non-confrontational, not a go-getter, optimistic, trustworthy, etc. Am I right?
Scripts in 3 hours.
Why does it make me smile knowing that Amarin had to publish it?
SARISSA's PRESENTATION
The greatest reading material I've ever read pertaining to a stock.
Thumbs up!
https://investor.amarincorp.com/node/22686/html
I think this is a fair question.
👋 @Amarincorp
— Raf 🍊 (@ra_fun) February 2, 2023
As a concerned shareholder of $AMRN, who has lost 90% of the stock value, I am curious about who is funding your new website https://t.co/IRv2nknzSP and the remainder of your fight against Sarissa & Alex Denner?
Am I?!
Each side is painting a picture. Unless something changes, the final images that are stuck in my head are:
Sarissa: a very relatable letter to shareholders
Amarin: an out-of-touch YouTube clip that is 2 days old & has 0 likes
I don't remember ever seeing something so lopsided.
Here is Denner saying what he's planning to do with Amarin without specifically saying it.
Thumbs up for Sarissa's masterpiece!
The BCBS-FEP fight is going to be a little tougher. Just spoke to my insurance, they said that they didn't receive the formulary exemption form that my doctor told me that he submitted last week.
But BCBS-FEP also told me that Vascepa isn't eligible for formulary exemption because it's a tier 2 drug - only tier 3 & higher are eligible. When asked why, they said that because substitutions are available for tier 2 drugs. I told them not for my condition and of course she didn't take care (at this point).
She said if the formulary exception gets denied (most likely scenario), I can always appeal, which I certainly will, like I did for my parents 2 days ago and won.
Let me know if anyone else is fighting.
And at the end of the day, Amarin is responsible for Amarin.
The overall market today is higher than it was pre-COVID.
Du didn't force Amarin to exclude their in-house (award winning Shero) biostatistician from testifying and/or presenting a paper DURING the trial that Bhatt coauthored AFTER the trial.
Unlike on Amarin's YouTube clip, comments are enabled here.
Please do comment.
👋 @Amarincorp
— Raf 🍊 (@ra_fun) February 1, 2023
Since you disabled comments on your SNL skit-like video, it is only fair for me to post a link to this video here and to allow shareholders to respond - comments ENABLED.
So let's hear it from shareholders #VASCEPA 🗣🗣🗣https://t.co/lpwiY9RdWk https://t.co/9ZdVEJyuMS
LOLOLOLOLOL I haven't laughed this hard in a long time.
That was for my parents (Emblem Health / Express Scripts)
Still waiting for the results of mine (BCBS-FEP).
As I said before, if they tell you to substitute V with GV or Lovaza, but once you tell them that you're taking Vascepa for CVD risk reduction, there is nothing they can do but to approve V
Yesterday, my parents' insurance rejected their doctor's appeal to cover Vascepa - it was rejected probably because the form wasn't filled out completely.
I called the insurer yesterday and filed an "oral appeal" of the denial - gave them a mouthful and then some.
Just received a voice mail from the insurer:
THE DENIAL WAS OVERTURNED!!!
Raf for the win!!!!!!
So Amarin are basically throwing a white flag in the USA!!!!!!!!!!!!!!!!!!!!
Vote blue.
Don't know how long, but today isn't their starting point. They should have it as their parallel plan all along, dating to at least September 24, 2018.
This is the most bizarre thing I've seen posted here.
How is what what you're saying here jive with what Dr Bhatt tweeted just 2 months ago?
I had assumed those would be worthwhile studies to do and be funded, but that did not happen. So, the only data (not anecdote) that exist are the data the FDA would have required and whatever internal data the company would have likely generated themselves (again, me assuming).
— Dr. Deepak L. Bhatt (@DLBHATTMD) November 6, 2022
Does your pharmacy auto default? Clearly not.
Generics don't have a CV label. When they sell GV, they claim that they don't know if it's for MARINE or CV indication. But a combo pill will only be for the CV indication, so the Generics cannot claim ignorance.
And as Duke said, patents too.
One of the main reasons that V scripts are horrible is because Amarin made a decision not to promote V anymore.... because Generics would reep benefits of these promotions, but without paying for it - I disagree with this approach, IMO they should have attacked Generics for not having a CVD label.
If Amarin make a combo pill, they would be the sole beneficiary of promoting it.
And if Amarin charges Kaiser roughly the same as Kaiser 2 pills individually?
Those voting for Amarin, don't forget to vote on February 30.
Scripts for week ending January 20, 2023
Drug Industry TRx: -3.1% w/w; +9.0% y/y
Vascepa
TRx 58,263; -3.7% (-2,240) w/w; -22.5% y/y
NRx 27,302; -5.0% (-1,446) w/w; -23.1% y/y
Ref 30,961; -2.5% (-793) w/w; -22.0% y/y
Fake Vascepa
TRx 47,587; +2.8% (+1,283) w/w; As % of total V: 45.0%
NRx 23,730; +2.7% (+614) w/w; As % of total V: 46.5%
Ref 23,857; +2.9% (+670) w/w; As % of total V: 43.5%
Fake Vascepa by Manufacturer
Hikma - TRx 16,982; -115 w/w; Generic share 35.7%; Total V share 16.0%
Reddy - TRx 21,704; +1,686 w/w; Generic share 45.6%; Total V share 20.5%
Apotex - TRx 8,490; -285 w/w; Generic share 17.8%; Total V share 8.0%
Teva - TRx 411; +98 w/w; Generic share 0.9%; Total V share 0.4%
Vascepa + Fake Vascepa
TRx 105,850; -0.9% (-956) w/w; +4.7% y/y
NRx 51,032; -1.6% (-832) w/w; +0.3% y/y
Ref 54,818; -0.2% (-124) w/w; +9.2% y/y
Lovaza (Fake & Brand)
TRx 64,905; -1.8% (-1,182) w/w; +4.8% y/y
NRx 32,433; +0.3% (+83) w/w; +0.9% y/y
Ref 32,473; -3.7% (-1,265) w/w; +9.0% y/y
Some do, some don't.
This that do, why would they not cover the combo pill?
There you go again, change the entire narrative.
Your new narrative is: would you pay 5x more for a combo pill?
But is that the real scenario, A) X$ for two separate pills or B) 5X$ for a combo pill?
If your insurance covers separate pills, why would it NOT cover a combo pill?
Why didn't you know this? Not you specifically, Study, "you" could be substituted for anyone here, myself included.
These guys (Amarin) do not seem to be serious about selling Vascepa.
Excellent question.
We discuss anything and everything on this board. The fact that nearly everyone here didn't have a clue how on how BLINKRX works, tells you everything about Amarin's effectiveness of promoting it.
If we you know, public and doctors certainly don't know.
Hopefully this is helpful to some...
Just had a conversation with a BLINKRX employee:
If you have a commercial insurance or no insurance & transfer your prescription of VASCEPA to BLINKRX, you are guaranteed to pay no more than $99 / month.
So if you currently pay $9 / month with insurance, you will still pay $9 / month with BLINKRX. But if insurance won't cover Vascepa and let's say you would pay $300 / month after Amarin's savings card, you will pay only $99 / month with BLINKRX.
If you have any government-funded insurance (Medicare Part D), BLINKRX won't work with you. Use your common sense, perhaps stick to don't ask / don't tell.
Lastly, BLINKRX will not help you fight with your insurance (to get formulary exemption or on a lower tier), that's on you. But after that fight, you can switch to BLINKRX and they will mail your monthly supply.